LONDON, GREATER LONDON, UNITED KINGDOM, May 28, 2025 /EINPresswire.com/ -- What Is The Projected Market Size Of Renin-Angiotensin-System RAS-Acting Agents Market? According to recent data, the ...

The addition of SGLT2i to RAASi was associated with lower hyperkalemia risk among patients with diabetes, heart failure, or CKD.

Researchers have found that prescribing guideline-directed medical treatment (GDMT), regardless of the number of medications, ...

In summary, this study shows that canagliflozin is more than just a diabetes drug—it is also a powerful protector of kidney ...

Secondary hypertension is when your blood pressure gets elevated due to another health condition or medications. On World ...

What is renin angiotensin aldosterone? The renin-angiotensin-aldosterone system (RAAS) in your body helps control your blood pressure and blood volume. It includes renin (an enzyme), and the ...

Please provide your email address to receive an email when new articles are posted on . Dysregulated aldosterone production, sometimes driven by obesity, can cause hypertension. Targeted therapies ...

The novel selective aldosterone synthase inhibitor BI 690517 (up to 10 mg daily) with concurrent renin-angiotensin-system (RAS) inhibition, with or without the SGLT2 inhibitor empagliflozin ...

a Multivariate model adjusting for cancer therapy including antimetabolites, Vascular endothelial growth factors inhibitors, taxanes, tyrosine kinase inhibitors, monoclonal antibodies, vinca alkaloids ...